CADTH conducted a Health Technology Review on remdesivir — an antiviral drug currently being used to treat COVID-19. Remdesivir was approved in Canada on July 27, 2020 to treat adults and adolescents with severe symptoms of COVID-19 who have pneumonia and require extra oxygen. Four randomized controlled trials were identified and included in the review.

On October 15, 2020, interim study results from the World Health Organization’s Solidarity Trial were released in pre-print (ISRCTN83971151). The Solidarity Trial is a large, international, adaptive, open-label, randomized controlled trial launched by the World Health Organization and other partners to evaluate several treatments for COVID-19. The interim results report on the findings of four separate treatments compared with local standard of care in hospitalized patients with COVID-19: remdesivir, lopinavir and ritonavir, interferon beta-1a, and hydroxychloroquine. The primary outcome was in-hospital mortality. The intention-to-treat analyses included 11,255 patients enrolled from 405 hospitals in 30 countries, including Canada. No treatment had a statistically significant reduction in 28-day in-hospital mortality compared with its control. Caution should be exercised in interpreting any interim study results. In addition, pre-print reports have not been peer-reviewed. Publication of full study results in a peer-reviewed journal are pending.

CADTH is in the progress of updating the Health Technology Review on remdesivir and will include a critical appraisal of the results of the Solidarity Trial when it is reported in a peer-reviewed publication.

Link to Report

Remdesivir: Evidence Review and Appraisal (updated Oct 22, 2020)


Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.